中

Achieve precision medicine with disruptive strategies

We focus on developing the next generation of targeted anticancer drugs by designing the novel structure of small molecules.
Our Science

Achieve precision medicine with disruptive strategies

We focus on developing the next generation of targeted anticancer drugs by designing the novel structure of small molecules.
Our Science

Mission drives innovation, and innovation improves quality of life

We bring solutions to cancer drug resistance from our deeply integrated strength in chemistry, biology and medicine.
About Us

The next generation of cancer therapies that meet urgent clinical needs

We are building a pipeline of targeted cancer therapies by harnessing our artificial intelligence platform and expertise of structure-based design.
Our Pipeline

TargetRx announces FIH of the next generation ALK inhibitor TGRX-326

The first subject has been dosed in the Phase 1 study at the SYSUCC for TGRX-326, a next-generation ALK/ROS1 dual-target inhibitor, which is being developed as a potential treatment for patients with non-small cell lung cancer.
News

Fighting cancer is our mission, make it yours

Join world-class innovative and dynamic team who are dedicated to bringing differentiated therapies to patients.
Join Us

Fighting cancer is our mission, make it yours

Join world-class innovative and dynamic team who are dedicated to bringing differentiated therapies to patients.
Join Us

About Us

R&D

Pipeline

News

Careers

Contact

  • Tel: +86-0755-86934300
  • Rm 301, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
  • E-mail: targetrx@tjrbiosciences.com

Follow Us

Copyright © 2021 Shenzhen TargetRx, Inc.
粤ICP备2021119553号